Related Experiment Videos
Sudden cardiac death--an approach to management of the patient at risk
Insights
Sudden cardiac death from ventricular fibrillation is a major concern. Effective antiarrhythmic therapy, guided by continuous EKG monitoring and exercise testing, significantly reduces mortality in high-risk patients.
Area of Science:
- Cardiology
- Electrophysiology
- Preventive Medicine
Background:
- Sudden cardiac death (SCD) due to ventricular fibrillation (VF) is a leading cause of mortality in industrialized nations.
- Patients at increased risk often exhibit high-grade ventricular arrhythmias and impaired left ventricular function.
- Risk factors include sympathetic overactivity, electrolyte imbalances, coronary artery spasm, and thrombotic coronary occlusion.
Purpose of the Study:
- To outline diagnostic and therapeutic strategies for managing patients at risk of sudden cardiac death.
- To establish criteria for initiating and evaluating antiarrhythmic therapy.
- To assess the impact of effective arrhythmia control on long-term mortality.
Main Methods:
- Continuous 24-hour EKG monitoring and exercise EKG for arrhythmia detection and treatment assessment.
- Ambulatory EKG monitoring and exercise testing after drug discontinuation for treatment evaluation.
- Programmed electrical stimulation for guiding therapy in select cases.
- Acute drug administration and 72-hour maintained therapy assessment.
Main Results:
- Effective antiarrhythmic treatment is defined by complete arrhythmia suppression or significant reduction in ventricular ectopy.
- Inadequate arrhythmia control is associated with a markedly higher yearly mortality rate (43.6-56%) compared to successfully controlled patients (2.3-2.8%).
- Arrhythmia aggravation occurred in 11.1% during acute drug testing.
Conclusions:
- Continuous EKG and exercise testing are crucial for diagnosing and managing high-grade ventricular arrhythmias.
- Antiarrhythmic therapy is indicated for specific high-risk patient groups, with treatment efficacy evaluated through objective monitoring.
- Successful control of malignant arrhythmias significantly improves long-term survival, highlighting the importance of tailored therapeutic strategies.
Abstract:
Sudden cardiac death due to ventricular fibrillation is the most common cause of death in industrialized countries. Patients with an increased risk of sudden cardiac death may be found to have, in addition to high-grade ventricular arrhythmias, impaired left ventricular function. Mechanisms responsible for precipitation of ventricular fibrillation include risk factors such as increased sympathetic nervous system activity, electrolyte disturbances, coronary artery spasm and transient, thrombotic coronary artery occlusion. For detection of high-grade arrhythmias as well as for assessment of treatment, continuous 24-hour EKG monitoring and exercise EKG should be employed. The indication for antiarrhythmic therapy should be regarded as established in patients successfully resuscitated after unexpected ventricular fibrillation as well as in patients status-post myocardial infarction, with angina pectoris, cardiomyopathies, QT-prolongation, mitral valve prolapse, congenital or other markedly symptomatic heart disease and high-grade ventricular arrhythmias. The treatment initiated, after discontinuation of all antiarrhythmic drugs for at least four half lives and ambulatory EKG monitoring for 48 hours as well as maximal symptom-limited exercise testing, should be evaluated after acute drug administration and after 72 hours of maintained therapy with the aid of continuous EKG monitoring and exercise EKG. In patients with a history of malignant arrhythmias in whom no evidence of high-grade ventricular arrhythmias can be found in either the continuous EKG recording or in the exercise EKG, initiation of drug treatment should be based on the results of programmed electrical stimulation. Effective treatment can be assumed on documentation of complete suppression of arrhythmias grade IVb and V or prevention of precipitation of ventricular tachycardias, respectively, as well as 90% reduction of grade IVa and 50% reduction of premature ventricular beats. During acute testing, aggravation of arrhythmias after administration of antiarrhythmic drugs was seen in 11.1%. While the yearly mortality of successfully controlled patients ranged between 2.3 and 2.8%, the yearly mortality rate in those in whom the arrhythmias were inadequately controlled ranged from 43.6 to 56%.